key: cord-1036186-93oexm0m
authors: Casado, José L.; Häemmerle, Johannes; Vizcarra, Pilar; Velasco, Hector; Velasco, Tamara; Fernandez-Escribano, Marina; Vallejo, Alejandro
title: SARS CoV-2 infections in health care workers with pre-existing T cell response: a prospective cohort study
date: 2021-03-02
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.02.020
sha: 8b23dcdabdac5d73ec88b6dcb0df19de3c204369
doc_id: 1036186
cord_uid: 93oexm0m

OBJECTIVE: T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are observed in unexposed individuals. We evaluated the impact of this pre-existing cellular response on incident SARS CoV-2 infections. METHODS: Follow up study of 38 seronegative health care workers (HCWs) with previous evaluation of CD8+ and CD4+ T-cell response after stimulation with SARS-CoV-2 structural proteins. Infection was considered in presence of a positive reverse transcription (RT)-PCR test and/or confirmed seroconversion. RESULTS: Twenty of the 38 HCWs included (53%) had a previous specific CD8+ T cell response to peptides encompassing the spike (S) protein in 13 (34%), the membrane (M, 17, 45%), or/and the nucleocapsid (N, 3, 8%). During a follow up of 189 days (interquartile range, IQR, 172 to 195), 11 (29%) HCWs had a RT-PCR positive test (n=9) or seroconverted (n=2). Median duration of symptoms was 2 days (IQR, 0-7), and time to negative RT-PCR was 9 days (IQR, 4-10). Notably, six incident infections (55%) occurred in HCWs with pre-existing T-cell response (30% of those with cellular response), who showed a significant lower duration of symptoms (three were asymptomatic). Three of the six HCWs having previous T-cell response continued testing seronegative. All the infected patient developed a robust T-cell response to different structural SARS-CoV-2 proteins, especially to protein S (91%). CONCLUSION: Pre-existing T-cell response does not seems to reduce incident SARS-CoV-2 infections, but it may contribute to asymptomatic or mild disease, rapid viral clearance and differences in seroconversion.

Objective: T-cell responses against severe acute respiratory syndrome coronavirus 24 2 (SARS-CoV-2) are observed in unexposed individuals. We evaluated the impact of 25 this pre-existing cellular response on incident SARS CoV-2 infections. and time to negative RT-PCR was 9 days (IQR, 4-10). Notably, six incident infections 36 (55%) occurred in HCWs with pre-existing T-cell response (30% of those with cellular 37 response), who showed a significant lower duration of symptoms (three were 38 asymptomatic). Three of the six HCWs having previous T-cell response continued 39 testing seronegative. All the infected patient developed a robust T-cell response to 40 different structural SARS-CoV-2 proteins, especially to protein S (91%).

Data from other coronavirus infections demonstrated that cellular immunity is a 48 determinant for long-term protection [1] , a crucial fact since antibody levels against 49 SARS-CoV-2 wane quickly during the follow up [2, 3] . Notably, recent studies 50

described T-cell responses to viral peptides in patients not exposed to SARS-CoV-2, 51 probably in relation with cross-reactivity to common coronavirus infections [4] . Characteristics of these 11 infected HCWs are detailed in Table 1 . and with response to protein S in 10 cases (91%) (Figure 1B , see also web-only 121

Supplementary Table S1 and Figure S1 ). suggest that these pre-existing T-cells were mainly cross-reactive, with comparable 129 affinity to SARS CoV-2 and common cold coronaviruses [4, 9] . This fact could also 130 be suggested by the predominance of response to protein M in our study, which 131 showed a 90% of structural identity with other coronavirus [10]. 132

Nonetheless, no studies have addressed the incidence and clinical importance of this 133 pre-existing T-cell response. In our study, 6 of the 11 incident infections (55%) were 134 observed in HCWs with pre-existing T-cell immunity. As expected, cellular response 135 does not provide sterilizing immunity, and indeed, it could be associated with 136 transmission, as we showed with one HCW in our cohort. However, as demonstrated 137 with influenza, some degree of preexisting cellular immunity correlate with less 138 severe disease [11] . This could explain the short duration of symptoms and rapid viral 139 clearance, although we cannot exclude the beneficial effect of the young age and the 140

We offer data about the functional capacity and evolution of pre-existing T-cell 142 responses. HCWs who acquired COVID-19 (3/7 and 3/13 with response to protein M 143 and S, respectively) had previously a weaker IFN-γ producing CD8+ T-cells 144 response. It is not known which is the most protective profile of cellular response, proteins [3, 12] and we observed a rapid and extense SARS-CoV-2 specific CD8+ T-147

Our study has several limitations, including the small number of HCWs that limits 149 statistical associations. First, the possibility of previous asymptomatic infections and 150 misclassification was possible but unlikely because of the high sensitivity of 151 serological test, and the differences in T-cell responses with convalescent patients. 152

Second, initial T-cell evaluation was performed 5-6 months before infection, and we 153 cannot preclude a slight decrease in T-cell immunity during this period. Finally, we 154 did not include T-cell response to other structural proteins, as ORF1a, which have 155 been showed as immunodominant in some studies [13] . 156

In conclusion, we found that 30% of HCWs with pre-existing T-cell response acquired 157 a SARS-CoV-2 infection during a 6-months follow up, confirming that symptomatic, 158 transmissible SARS CoV-2 infection is possible in the presence of previous cellular 159 immunity. However, our data suggest that this T-cell background, although weak, 160 could modify seroconversion rates and could help to attenuate the clinical course, 161 explaining differences in duration and severity of the disease. 162

We thank to Ana Abad for database management. 165

All the authors declare no conflict of interest. All research was conducted within the 167 guidelines of ethical principles, and local legislation. 168

Jose L Casado and Alejandro Vallejo contributed equally to this work. JC and AV 170 conceived of and designed the study, analyzed the results, and wrote the manuscript. 171

All other authors conducted the study and collected data, revised the manuscript, and 172 approved the final version. 173

No external funding was received for this work, and it was supported by departmental 175 discretionary funds available to the first corresponding author. 

T cell-mediated immune response to 179 respiratory coronaviruses

Antibodies After Mild Infection Among Frontline Health Care Personnel in a 182

Multistate Hospital Network -12 States

Convalescent Individuals with Asymptomatic or Mild COVID-19

Selective and cross-reactive SARS-CoV-2

T cell epitopes in unexposed humans

Clinical course and risk factors for mortality of adult 190 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Targets of T Cell Responses to 193

SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed 194 Individuals

SARS-CoV-2-specific T cell 196 immunity in cases of COVID-19 and SARS, and uninfected controls

SARS-CoV-2-reactive T cells in healthy 199 donors and patients with COVID-19

SARS-CoV-2-derived peptides define 201 heterologous and COVID-19-induced T cell recognition

A structural analysis of M protein in 203 coronavirus assembly and morphology

Preexisting influenza-specific CD4+ T 205 cells correlate with disease protection against influenza challenge in humans

Characterization of pre-existing and 208 induced SARS-CoV-2-specific CD8(+) T cells

CD8+ T cell responses in convalescent 210

COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome 211 and show kinetics of early differentiation. bioRxiv 2020. 212 workers; RT-PCR, reverse transcriptase-PCR; 1 chi-square test; 2 aerosol-generating 219 procedures included airway suction

bronchoscopy, endotracheal intubation, tracheostomy, nebulizer treatment, sputum 221 induction, positive pressure ventilation, manual ventilation, and cardiopulmonary 222 resuscitation; 3 Time from study inclusion to positive RT-PCR testing or final serologic 223 testing, depending of the group